Vor Biopharma Inc (VOR) USD0.0001

Sell:$1.38Buy:$1.39$0.06 (4.48%)

NASDAQ:1.35%
Market closed | Prices delayed by at least 15 minutes
Sell:$1.38
Buy:$1.39
Change:$0.06 (4.48%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$1.38
Buy:$1.39
Change:$0.06 (4.48%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.

Key people

Robert Ang
President, Chief Executive Officer, Director
Han Choi
Chief Financial Officer
Tirtha Chakraborty
Chief Scientific Officer
Eyal C. Attar
Chief Medical Officer
Matthew R. Patterson
Non-Executive Independent Chairman of the Board
Daniella Beckman
Independent Director
Erez Kalir
Independent Director
David Charles Lubner
Independent Director
Sven Ante Lundberg
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US9290331084
  • Market cap
    $177.19m
  • Employees
    168
  • Shares in issue
    124.78m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.